awmsg logo



denosumab (Xgeva®)


Reference No. 1870

Publication date:
10/12/2015


Appraisal information

denosumab (Xgeva®) 120 mg solution for injection


Company: Amgen Ltd
BNF category: Endocrine system
NMG meeting date: 07/10/2015
AWMSG meeting date: 11/11/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3815
Ministerial ratification: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Denosumab (Xgeva®) is recommended for use within NHS Wales for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download